Evommune, Inc. (EVMN)

NYSE

$9,74

$+0,68

(+7,20%)

Pre-Market

Evommune, Inc. (EVMN) Live Price Chart

Last updated: ⁦2026-09-22 11:49:20⁩. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.

Summary

Evommune, Inc. (EVMN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $9,74, with a market capitalization of $350,22M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9,20 to $33,20. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$350,22M
Open	$9,53
Day's High	$33,20
Day's Low	$9,20
Previous Close	$9,45
Volume	314,00
Average Volume	869,19K
P/E Ratio	--
52-Week High	$33,20
52-Week Low	$9,20
Dividend Yield	--
Earnings Date	--

Evommune, Inc. (EVMN) Pre-Market Stock Price

Evommune, Inc. (EVMN) is trading at $9,74 in pre-market trading as of 2026-09-22 11:40:00, up 3,02% ($0,29) from the previous close of $9,45

Pre-market trading shows how investors are pricing EVMN before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.

Evommune, Inc. (EVMN) 7-Day Stock Price Change

Over the past seven days, Evommune, Inc. (EVMN) moved from $10,54 to $9,74, representing a decline of 7,64% ($0,80).

The stock traded between $9,20 and $10,82 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.

The average daily volume was 618,68 thousand shares, down versus the previous seven-day period, indicating lower trading activity.

EVMN 52-Week Price Position

Position in Range: 2,2%

52W Low$9,20

52W High$33,20

EVMN is currently trading at $9,74, placing it 2,2% of the way from its 52-week low of $9,20 to its 52-week high of $33,20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Evommune, Inc. (EVMN)?

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Evommune, Inc. Information

Industry	PHARMACEUTICAL PREPARATIONS
Employees	48
Exchange	NYSE
Company Website	https://www.evommune.com

How to Buy Evommune, Inc. (EVMN) Stock on MEXC

Eligible investors can buy real shares of Evommune, Inc. (EVMN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for EVMN and Place Your Order

Open the RealStocks trading page and search for EVMN. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Evommune, Inc. (EVMN) stock price today?

Evommune, Inc. (EVMN) is currently trading at $ 9,74, up 3,02% ($0,29) from the previous close of $ 9,45. Intraday prices update in real time during regular trading hours.

2.Is EVMN stock going up or down today?

As of 2026-09-22 11:40:00, EVMN is trading at $ 9,74, up 3,02% ($0,29) from its previous close of $ 9,45. The stock has traded between $ 9,20 and $ 33,20 during today’s regular session. Past price movements do not guarantee future results.

3.What is EVMN pre-market price?

As of 2026-09-22 11:40:00, EVMN is trading at $ 9,74 in pre-market trading, up 3,02% ($0,29) from the previous close of $ 9,45. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is EVMN after-hours price?

As of 2026-09-22 11:40:00, EVMN is trading at $ 9,53 in after-hours trading, up 0,79% ($0,08) from the regular-session close of $ 9,45. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is EVMN stock trading now?

EVMN trades on the NYSE exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does EVMN sit relative to its 52-week high and low?

Over the past 52 weeks, EVMN has traded between a low of $ 9,20 and a high of $ 33,20. At $ 9,74, the stock is positioned 2,2% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Evommune, Inc. in?

Evommune, Inc. (EVMN) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Evommune, Inc.'s market capitalization and where is it listed?

Evommune, Inc. is listed on the NYSE exchange with a market capitalization of $ 350,22M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is EVMN valued in terms of P/E ratio and EPS?

EVMN trades at a P/E ratio of --, based on trailing-twelve-month EPS of $ -2,61. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Evommune, Inc. pay a dividend?

Evommune, Inc. pays an indicated annual cash dividend of $ 0,00 per share, with a current dividend yield of 0,00% based on the latest share price. Dividend policies are subject to change at the board's discretion.